FLAGSTAFF, Ariz.--(BUSINESS WIRE)--W. L. Gore & Associates (Gore) recently took part in the fifth annual Vascular Interventional Advances (VIVA) Conference in Las Vegas, where the focus was on new technologies for combating peripheral vascular disease (PVD), also called peripheral arterial disease (PAD). At VIVA, two new studies were announced (Gore VIPER Study and Gore PRODIGY Study) that are each designed to collect important data about the performance of heparin-bonded vascular grafts in treating lower-limb PVD. In the US alone, as many as 12 million people suffer from some form of the disease, which manifests as a buildup of plaque in the wall of an artery and results in either narrowing or blocking of the artery, limiting blood flow to the limbs.
